OncoMatch/Clinical Trials/NCT05184088
Efficacy of [18F]Florbetaben PET for Diagnosis of Cardiac AL Amyloidosis
Is NCT05184088 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies [18F]florbetaben for cardiac amyloidosis.
Treatment: [18F]florbetaben — This is an open-label, multi-center pivotal Phase 3 study to visually and quantitatively assess PET images obtained after single application of 300 MBq \[18F\]florbetaben and PET scanning of patients with suspected cardiac amyloidosis.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Prior therapy
Cannot have received: radiopharmaceutical
Having been administered a radiopharmaceutical within 10 radioactive half-lives prior to study drug administration in this study
Lab requirements
Liver function
Severe hepatic impairment (AST/ALT >5 x ULN; bilirubin >3 x ULN) [excluded]
Severe hepatic impairment (AST/ALT >5 x ULN; bilirubin >3 x ULN) [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- St Luke's Hospital · Kansas City, Kansas
- University of Pennsylvania · Philadelphia, Pennsylvania
- University of Pittsburgh · Pittsburgh, Pennsylvania
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify